Chronically elevated blood sugar could increase risk of dementia in older women, according to a new four-year study. This is the first study to examine the link between glycosylated hemoglobin and cognitive problems and is published in the Volume 10, Number 4 issue of the Journal of Nutrition, Health, and Aging.
"We already know there's a connection between diabetes and cognitive problems," says lead author Kristine Yaffe, MD, a staff physician at the San Francisco VA Medical Center and a professor of psychiatry, neurology, and epidemiology at the University of California, San Francisco. "We were interested in what this measurement would tell us about a group of women with and without diabetes who were followed for four years. Nobody has really looked at that before."
The glycosylated hemoglobin test measures the percentage of hemoglobin - the oxygen-bearing protein in red blood cells - that is bound to glucose. Unlike the standard diabetic blood sugar test, which measures blood sugar at the moment of testing, glycosylated hemoglobin is considered an accurate measure of blood sugar levels over the course of two to four months preceding the test. A result of seven percent or less indicates good long-term blood sugar control.
Women with a glycosylated hemoglobin of seven percent or higher at baseline were four times more likely to develop MCI or dementia than women who tested at less than seven percent.
When the 53 women in the study known to have diabetes at baseline were excluded from the results, there was still a statistically significant association between elevated glycosylated hemoglobin and the risk of MCI or dementia.
The authors conclude, "This finding supports the hypothesis that abnormal glycemic control is linked to an increased risk of developing cognitive impairment and dementia in elderly women."
The authors note that there are a number of possible reasons why chronically high blood sugar may cause cognitive impairment, ranging from the overall effects of diabetic complications to direct and indirect brain damage caused by high blood sugar to a possible association between the enzyme that degrades insulin and the development of Alzheimer's disease.
"Type 2 diabetes is a very common and growing problem," notes Yaffe. "The point is that now you can identify people who are at risk for MCI or dementia and monitor them closely with glycosylated hemoglobin. I think we need to take these people who are at risk and see whether we can target them for trials or interventions for better blood glucose control."
Co-authors of the study were Terri Blackwell, MS, of California Pacific Medical Center; Rachel Whitmer, PhD, of Kaiser Permanente Division of Research; Katherine Kreuger, MD, of Eli Lilly and Company; and Elizabeth Barrett-Connor, MD, of UC San Diego.
The research was supported by grants from the National Institutes of Health, the Mount Zion/UCSF Fund for Women's Health, and the Paul Beeson Faculty Scholars in Aging. The parent trial, of which the current study was a part, was funded by Eli Lilly and Company.
SFVAMC has the largest medical research program in the national VA system, with more than 200 research scientists, all of whom are faculty members at UCSF.
UCSF is a leading university that consistently defines health care worldwide by conducting advanced biomedical research, educating graduate students in the life sciences, and providing complex patient care.
Source: Steve Tokar
415-221-4810 Source: Eurekalert